Clinical observation of Stulln eye drops with Sodium hyaluronate eye drops for dry eye disease

Clinical observation of esculin and digitalisglycosides eye drops with 0.3% sodium hyaluronate eye drops for dry eye disease: a randomized controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400093427

Enrollment

Unknown

Registered

2024-12-04

Start date

2024-10-01

Completion date

Unknown

Last updated

2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dry eye

Interventions

Hialid group:0.3% sodium hyaluronate eye drops

Stulln group:esculin and digitalisgIycosides eye drops

Combined group:esculin and digitalisgIycosides eye drops, and 0.3% sodium hyaluronate eye drops

Eligibility

Sex/Gender

All

Age

22 Years to 64 Years

Inclusion criteria

Inclusion criteria: (1) Subjective symptoms and tear break-up time (TBUT) 18 years old.

Exclusion criteria

Exclusion criteria: (1) Patients who require the use of intraocular pressure-lowering, anti-inflammatory, and immunosuppressive drugs; (2) Those with concurrent conditions such as glaucoma, conjunctivitis, intraocular infection, and nasolacrimal duct obstruction; (3) A history of ocular surgery in the past 3 months; (4) Severe conditions affecting the heart, kidneys, or liver; (5) A history of allergies to the selected drugs; (6) Pregnant or lactating women.

Design outcomes

Primary

Measure	Time frame
ocular surface disease index;tear break up time;Schirmer I test;corneal fluorescein staining;	—

Secondary

Measure	Time frame
best-corrected vision;intraocular pressure;Lipid layer thickness of the tear film;	—

Countries

China

Contacts

Public ContactJie Ying

Capital Medical University, Beijing Tongren Hospital

jie_yingcn@aliyun.com+86 136 9357 2296

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026